Entera Bio Ltd.

NasdaqCM:ENTX Stock Report

Market Cap: US$67.0m

Entera Bio Management

Management criteria checks 1/4

Entera Bio's CEO is Miranda Toledano, appointed in Jul 2022, has a tenure of 3.5 years. total yearly compensation is $1.15M, comprised of 36.5% salary and 63.5% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $309.67K. The average tenure of the management team and the board of directors is 1.7 years and 4.9 years respectively.

Key information

Miranda Toledano

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage36.47%
CEO tenure3.5yrs
CEO ownership0.5%
Management average tenure1.7yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jul 17
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Dec 07
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Jul 12
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

May 31
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Feb 15
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Oct 13
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans?

Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M

Aug 11

We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Jun 10
We Think Entera Bio (NASDAQ:ENTX) Needs To Drive Business Growth Carefully

Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

Jan 21
Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth

We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Oct 06
We're Interested To See How Entera Bio (NASDAQ:ENTX) Uses Its Cash Hoard To Grow

Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

Jun 19
Here's Why We're Not Too Worried About Entera Bio's (NASDAQ:ENTX) Cash Burn Situation

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

Mar 20
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate

CEO Compensation Analysis

How has Miranda Toledano's remuneration changed compared to Entera Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$419k

-US$10m

Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$9m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$950kUS$338k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$795kUS$231k

-US$13m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$82kn/a

-US$12m

Compensation vs Market: Miranda's total compensation ($USD1.15M) is above average for companies of similar size in the US market ($USD572.27K).

Compensation vs Earnings: Miranda's compensation has increased whilst the company is unprofitable.

CEO

Miranda Toledano (48 yo)

3.5yrs
Tenure
US$1,149,000
Compensation

Ms. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since November 2021.She serve...

Leadership Team

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director3.5yrsUS$1.15m0.46%
$ 309.7k
Dana Yaacov-Garbeli
Chief Financial Officer6.6yrsUS$438.00k0.19%
$ 126.6k
Hillel Galitzer
Chief Operating Officer11.9yrsUS$531.00k0.074%
$ 49.8k
Gregory Burshtein
Chief of Research & Development1.7yrsno data0.11%
$ 73.0k
Rachel Wagman
Chief Clinical Advisor1.7yrsno datano data
Cherin Smith
Executive VP & Head of Clinical Operations1yrno datano data
Constantin Itin
Head of Biopharmaceutics & Bioanalytics1yrno datano data
1.7yrs
Average Tenure
47.5yo
Average Age

Experienced Management: ENTX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Miranda Toledano
CEO & Director7.3yrsUS$1.15m0.46%
$ 309.7k
Steven Goldstein
Member of Clinical & Scientific Advisory Board2.8yrsno datano data
Gerald Lieberman
Independent Chairman of the Board11.8yrsUS$124.90k0.79%
$ 530.4k
Gerald Ostrov
Independent Director7yrsUS$107.97k0.16%
$ 110.5k
Yonatan Malca
Independent Director15yrsUS$113.00k0.17%
$ 113.0k
Haya Taitel
Non-Employee Independent Director2.6yrsUS$97.00k0.20%
$ 132.8k
Sean Ellis
Independent Director6.6yrsUS$102.04k0.35%
$ 233.7k
John Bilezikian
Member of Scientific Advisory Boardno datano datano data
Maria Brandi
Member of Scientific Advisory Boardno datano datano data
Felicia Cosman
Chairman of Scientific Advisory Board3.2yrsno datano data
Serge Ferrari
Member of Scientific Advisory Board2yrsno datano data
Bente Langdahl
Member of Scientific Advisory Board2yrsno datano data
4.9yrs
Average Tenure
62yo
Average Age

Experienced Board: ENTX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/14 06:29
End of Day Share Price 2026/01/14 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Entera Bio Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
null nullCG Capital
Raghuram SelvarajuH.C. Wainwright & Co.